Table 1.
Y56H- grazoprevir |
Y56H-danoprevir | Y56H/D168A- danoprevir |
|
---|---|---|---|
PDB code | 6C2M | 6C2O | 6C2N |
Resolution | 1.86 Å | 1.18 Å | 1.80 Å |
Space group | P21 | P212121 | P212121 |
Twin Law | h,-k,-h-l | ||
Twin Fraction | 0.26 | ||
Molecules in AUa | 4 | 1 | 1 |
Cell dimensions: | |||
a (Å) | 56.6 | 55.4 | 60 |
b (Å) | 103.3 | 59.0 | 55.4 |
c (Å) | 74.0 | 60.0 | 58.9 |
β (°) | 90 | 90 | 90 |
Completeness (%) | 96.0 | 99.8 | 96.4 |
Total reflections | 208132 | 528153 | 139059 |
Unique reflections | 63506 | 65383 | 18030 |
Average I/σ | 11.4 | 18.5 | 17.8 |
Redundancy | 3.3 | 8.1 | 7.7 |
Rsym (%)b | 6.6 (28.1) | 6.9 (41.1) | 9.8 (29.9) |
RMSDc in: | |||
Bond lengths (Å) | 0.005 | 0.015 | 0.009 |
Bond angles (°) | 0.9 | 1.9 | 1.3 |
Rfacoor (%)d | 18.1 | 12.3 | 16.2 |
Rfree (%)e | 22.4 | 14.4 | 19.0 |
AU, asymmetric unit.
, where I = observed intensity, <I> = average intensity over symmetry equivalent; values in parentheses are for the highest resolution shell.
RMSD, root mean square deviation.
Rfree was calculated from 5% of reflections, chosen randomly, which were omitted from the refinement process.